Vanqua Bio
Dr. Ysselstein is the Director of Cell and Molecular Pharmacology at Vanqua. Prior to joining Vanqua, Dan worked at Northwestern University with Vanqua Co-Founder Dimitri Krainc. His work focused on using induced pluripotent stem cell-derived models to expand the understanding of basic CNS diseases including Parkinson’s and Frontal Temporal Dementia. Previously, Dan worked on alpha synuclein structural biology where he identified a new therapeutic approach to modulate alpha synuclein misfolding
Vanqua Bio
Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).